Directors’ shareholdings

RNS Number : 0465M
Advanced Medical Solutions Grp PLC
01 May 2015

1 May 2015

 

Advanced Medical Solutions Group plc

(“AMS” or the “Company”)

 

Directors’ shareholdings

 

Advanced Medical Solutions Group plc (AIM:AMS), the surgical and advanced woundcare specialist company, was informed today that the Trust which manages the Deferred Share Bonus Plan on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 30 April 2015, at a price of 141.5 pence per share on behalf Chris Meredith and Mary Tavener as part of the Deferred Share Bonus Plan and, under the terms of the Plan, these shares will be held in trust on their behalf.

 

Following these transactions the beneficial ownership of Chris Meredith and Mary Tavener is as follows:

Director

Date purchased

Shares Purchased

Resultant Holding

% of issued share capital

Chris Meredith, Chief Executive Officer

30 April 2015

2,684

1,187,891

0.6

Mary Tavener, Group Finance Director

30 April 2015

1,271

1,825,698

0.9

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

+44 (0) 1606 545508

Consilium Strategic Communications

Mary-Jane Elliot / Jonathan Birt / Matthew Neal / Ivar Milligan

+44 (0) 20 3709 5700

AMS@consilium-comms.com

Investec Bank plc (NOMAD & Broker)

Gary Clarence / Daniel Adams / Patrick Robb

+44 (0) 20 7597 5970

 

 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

 

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 472 employees. For more information please see www.admedsol.com.


This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSLLFSFEAILIIE